AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00634907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care warfarin dosing
Description: For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above.
Study NCT01820039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FertiScreen
Description: FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
Study NCT02192736 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trophic factors from umbilical cord mesenchymal stem cells
Study NCT04834037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
Study NCT01166542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REOLYSIN
Description: 3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
Study NCT01166542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
Study NCT01166542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
Study NCT01166542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
Study NCT01166542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
Study NCT01166542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03444038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study NCT00795665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
Study NCT00795665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
Study NCT02679677 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Whole Body Vibration
Description: The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
Study NCT02679677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
Study NCT04297280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: a PD-1 immune check inhibitor
Study NCT04297280 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
Study NCT03914313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Treatment plus VR
Description: The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
Study NCT03914313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Treatment plus VR
Description: The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
Study NCT00269048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848
Description: SB-480848
Study NCT00269048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00723554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-6
Description: Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
Study NCT00723554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-15
Description: Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
Study NCT00757601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1006
Description: MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose
Study NCT00757601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose
Study NCT00756288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical retinoid and blue-light therapy with photosensitizing agent
Description: Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
Study NCT00756288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy (PDT)
Description: Photo-therapy with sensitizing agent - apply to AKs at week 4
Study NCT02016300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unloader Bracing
Description: The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
Study NCT02016300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Bracing
Description: Microfracture performed with no post-operative unloader bracing
Study NCT00854321 — intervention group
Intervention type: DRUG
Intervention: rituximab
Description: rituximab two 1000 mg intravenous infusions separated by two weeks
Study NCT00854321 — intervention group
Intervention type: DRUG
Intervention: rituximab, observational study amon patients with active RA
Description: two 1000 mg intravenous infusions separated by 2 weeks
Study NCT01625637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAT-experiment
Description: This AAT condition trains kids to avoid cigarettes
Study NCT01625637 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AAT-placebo
Description: This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
Study NCT02463149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Chef Academy
Description: Nutrition and culinary curriculum delivered in the classroom
Study NCT00878995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testosterone
Description: Placebo (Saline) Testosterone given IM once per week.
Study NCT00878995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate 100 MG/ML
Description: Testosterone Enanthate 100mg/ml given once per week IM.
Study NCT02583503 — intervention group
Intervention type: RADIATION
Intervention: Hindfoot alignment view x ray
Description: Diagnostic x rays used to measure leg alignment.
Study NCT01031537 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FSME-IMMUN 0.5ml Baxter
Description: Vaccine
Study NCT02187978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early total enteral feeding (ETEF)
Description: In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
Study NCT02187978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional enteral feeding (CEF)
Description: CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
Study NCT02642666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's Yoga
Description: Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme.
Study NCT01644890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK105
Description: IV, Weekly
Study NCT01644890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV, Weekly
Study NCT01406678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
Study NCT02967224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine (U100)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02967224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT01508806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 0.75 mg, administered as a subcutaneous injection
Study NCT03327103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPION
Description: An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
Study NCT02784067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucraid
Description: Study drug
Study NCT02784067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucraid placebo
Study NCT02211170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, low dose
Study NCT02211170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, high dose
Study NCT02211170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02211170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) for endotoxin challenge
Study NCT02211170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) for endotoxin challenge
Study NCT01080365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: 500 mg commercial formulation film coated tablet, administered once daily
Study NCT01080365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606 (Bosutinib)
Description: 500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
Study NCT03966638 — intervention group
Intervention type: PROCEDURE
Intervention: Intra-meniscal injection of platelet-rich plasma
Description: Intra-meniscal injection of platelet-rich plasma under echographic control
Study NCT01162837 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BEAM device
Description: A red/blue LED device for the treatment of acne
Study NCT01469715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBP CGM
Description: Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active \& one mock device simultaneously during hyperglycemic \& hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 \& 4: Subjects will return to the research center approximately 24 \& 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 \& 5.
Study NCT03137199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSCs
Description: intravenous infusion of bone marrow-derived allogeneic stem cells
Study NCT04660916 — intervention group
Intervention type: DRUG
Intervention: Isotretinoin
Description: The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
Study NCT01650597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 2.5 - 500 mg oral
Description: Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
Study NCT01650597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
Study NCT01650597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 100 mg oral
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
Study NCT00327197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
Study NCT00327197 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
Study NCT00327197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
Study NCT01406678 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Coronary artery bypass surgery without remote ischemic preconditioning protocol
Study NCT01406678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isoflurane+sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study NCT01406678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoflurane+sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study NCT01745549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle for insulin pen, 4 mm long and with a diameter of 33 gauge
Study NCT01745549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
Study NCT01209325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Study NCT01209325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT04466670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetylsalicylic acid
Description: acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Study NCT04466670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Study NCT04466670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin nebulized
Description: unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
Study NCT02974543 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Treatment: unimodal auditory stimulation
Description: All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
Study NCT02974543 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Active Treatment: Bimodal auditory-somatosensory stimulation
Description: Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.
Study NCT03763097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic floor ultrasound
Description: Pelvic floor ultrasound will include transperineal and introital ultrasound
Study NCT02135913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: All subjects enrolled into the study will be prescribed standard of care Vitamin D